



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

March 17, 2005

FILE COPY

Rita F. Redberg, M.D., M.Sc., F.A.C.C.
UCSF National Center of Excellence in Women's Health
505 Parnassus Avenue, Suite M-1180
School of Medicine, Division of Cardiology
San Francisco, CA 94143-0124

Dear Dr. Redberg:

Your petition to the Food and Drug Administration concerning glycoprotein IIb/IIIa inhibitors – tirofiban, lamifiban, eptifibatide, and abciximab was received by this office on 03/16/2005. It was assigned docket number 2005P-0107/CP1 and it was filed on 03/17/2005. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

2005P-0107

ACK 1